메뉴 건너뛰기




Volumn 12, Issue 1, 2007, Pages 41-44

Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients

Author keywords

Autologous peripheral stem cell transplantation; DCEP; Multiple myeloma; Relapsed refractory

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; DCEP PROTOCOL; UNCLASSIFIED DRUG;

EID: 34249746735     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (30)

References (19)
  • 1
    • 0034235179 scopus 로고    scopus 로고
    • Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for multiple myeloma
    • Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355-357.
    • (2000) Blood , vol.96 , pp. 355-357
    • Cavo, M.1    Terragna, C.2    Martinelli, G.3
  • 2
    • 0021322023 scopus 로고
    • Effective treatment of advanced multiple myeloma resistant to alkylating agents
    • Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma resistant to alkylating agents N Engl J Med 1984; 310: 1353-1356.
    • (1984) N Engl J Med , vol.310 , pp. 1353-1356
    • Barlogie, B.1    Smith, L.2    Alexanian, R.3
  • 3
    • 0024357763 scopus 로고
    • Infusion of viacristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma
    • Samson R, Gaqminara E, Newland AC et al. Infusion of viacristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma Lancet 1989; 2: 882-885.
    • (1989) Lancet , vol.2 , pp. 882-885
    • Samson, R.1    Gaqminara, E.2    Newland, A.C.3
  • 4
    • 26844453345 scopus 로고    scopus 로고
    • Perspectives for combination therapy to overcome drug-resistant multiple myeloma
    • Catley L, Tai Y, Chauhan D, Andersen KC. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resistance Updates 2005; 8: 205-218.
    • (2005) Drug Resistance Updates , vol.8 , pp. 205-218
    • Catley, L.1    Tai, Y.2    Chauhan, D.3    Andersen, K.C.4
  • 5
    • 0035200513 scopus 로고    scopus 로고
    • DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
    • Lazzarino M, Corso A, Barbarano L et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28: 835-839.
    • (2001) Bone Marrow Transplant , vol.28 , pp. 835-839
    • Lazzarino, M.1    Corso, A.2    Barbarano, L.3
  • 6
    • 0036800307 scopus 로고    scopus 로고
    • A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma
    • Corso A, Arcaini L, Caberlon S et al. A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002; 87: 1041-1045.
    • (2002) Haematologica , vol.87 , pp. 1041-1045
    • Corso, A.1    Arcaini, L.2    Caberlon, S.3
  • 7
    • 0003247367 scopus 로고    scopus 로고
    • Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP): An effective regimen for relapse after high-dose chemotherapy and autologous transplantation
    • Munshi NC, Desihan KR, Jagannath S et al. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP): an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood 1996; 88 (Suppl 1): 586a.
    • (1996) Blood , vol.88 , Issue.SUPPL. 1
    • Munshi, N.C.1    Desihan, K.R.2    Jagannath, S.3
  • 8
    • 31344455109 scopus 로고    scopus 로고
    • Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma
    • Gojo I, Meisenberg B, Guo C et al. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 65-72.
    • (2006) Bone Marrow Transplant , vol.37 , pp. 65-72
    • Gojo, I.1    Meisenberg, B.2    Guo, C.3
  • 9
    • 0035045698 scopus 로고    scopus 로고
    • High-dose therapy and innovative approaches to treatment of multiple myeloma
    • Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol 2001; 38 (2 Suppl 3): 21-27.
    • (2001) Semin Hematol , vol.38 , Issue.2 SUPPL. 3 , pp. 21-27
    • Barlogie, B.1
  • 10
    • 20444433230 scopus 로고    scopus 로고
    • Bortezomib or high dose dexamethasone for relapsed multiple myeloma
    • Richardson PG, Sonneveld P, Schuster M et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
    • (2005) N Engl J Med , vol.352 , pp. 2487-2498
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.3
  • 11
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Desikan, R.3
  • 12
    • 11144356289 scopus 로고    scopus 로고
    • Pulsed cyclophosphamide, thalidomide and dexamethasone; an oral regimen for previously treated patients with multiple myeloma
    • Dimopoulos MA, Hamilos G, Zomas A et al. Pulsed cyclophosphamide, thalidomide and dexamethasone; an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-117.
    • (2004) Hematol J , vol.5 , pp. 112-117
    • Dimopoulos, M.A.1    Hamilos, G.2    Zomas, A.3
  • 13
    • 0037973279 scopus 로고    scopus 로고
    • A phase 2 study of bortezomib in relapsed, refractory myeloma
    • Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
    • (2003) N Engl J Med , vol.348 , pp. 2609-2617
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3
  • 14
    • 33745801771 scopus 로고    scopus 로고
    • Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    • Jagannath S, Richardson PG, Barlogie B et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929-934.
    • (2006) Haematologica , vol.91 , pp. 929-934
    • Jagannath, S.1    Richardson, P.G.2    Barlogie, B.3
  • 15
    • 30844443713 scopus 로고    scopus 로고
    • Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma
    • Cioli S, Leoni F, Gigli F, Rigac L, Bosi A. Low dose velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma. Leuk Lymphoma 2006; 47: 171-173.
    • (2006) Leuk Lymphoma , vol.47 , pp. 171-173
    • Cioli, S.1    Leoni, F.2    Gigli, F.3    Rigac, L.4    Bosi, A.5
  • 16
    • 33644916110 scopus 로고    scopus 로고
    • Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    • Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
    • (2006) J Clin Oncol , vol.24 , pp. 937-944
    • Berenson, J.R.1    Yang, H.H.2    Sadler, K.3
  • 17
    • 0036839013 scopus 로고    scopus 로고
    • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    • Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
    • (2002) Blood , vol.100 , pp. 3063-3067
    • Richardson, P.G.1    Schlossman, R.L.2    Weller, E.3
  • 18
    • 0034331194 scopus 로고    scopus 로고
    • Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy
    • Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
    • (2000) Blood , vol.96 , pp. 2943-2950
    • Hideshima, T.1    Chauhan, D.2    Shima, Y.3
  • 19
    • 33750607347 scopus 로고    scopus 로고
    • A randomized phase 2 study of lenalidomide therapy for patients with relapsed and refractory multiple myeloma
    • Richardson PG, Blood E, Mitsiades CS et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
    • (2006) Blood , vol.108 , pp. 3458-3464
    • Richardson, P.G.1    Blood, E.2    Mitsiades, C.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.